ChemioCare names new chief medical officer and CFO

ChemioCare USA Inc, a private biotech company focused on cancer care, announced Monday the appointment of Dr Jamie Oliver as its chief medical officer and Chris Chipman as chief financial officer.

“It is time to strengthen our management team and I am pleased to have been able to attract Jamie and Chris to our rapidly growing company,” said Pedro Lichtinger, CEO of New York-based ChemioCare, in a statement. “Our company has made substantial progress. We now have multiple proprietary transdermal patches in development focusing on new indications of generic medicines that will address significant unmet needs.” 

READ: ChemioCare initiates program in pediatric chemotherapy-induced nausea and vomiting

With more than 24 years of experience in the biotech and pharmaceutical sectors, Oliver is set to leverage his experience to guide product development, which is set to include the launch of a pair of Phase 3 studies in late 2019.

Before joining ChemioCare, Oliver was the chief scientific officer at Accelovance Inc, an oncology contract research organization. He also held the post of CEO at Phage Pharmaceuticals and worked as a principal at Trinity Drug Partners LLC.

In the course of his career, Oliver prepared more than 50 investigational new drugs and participated in a number of successful new drug applications to the Food and Drug Administration. He also boasts clinical experience in oncology, hematology, vaccines, infectious diseases, immunopharmacology, renal disease and transplantation.

Chipman, meanwhile, has more than two decades of experience as an accountant working with publicly traded companies across industries. Chipman has been a managing member of Chipman & Chipman LLC, a consulting firm that assists public companies with the preparation of reports, since November of 2000. Chipman also served as CFO and a secretary of Capital Gold Corp, a gold production and exploration company, from 2006 to 2011.

ChemioCare specializes in neutralizing chemotherapy-induced nausea and vomiting through its own transdermal patch technology. Its management is looking to take the company public in the first half of next year.

Contact Ellen Kelleher at [email protected]

Story by ProactiveInvestors